Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Global Blood Therapeutics Names Hing Sham Senior Vice President of Chemistry

Published: Tuesday, August 05, 2014
Last Updated: Tuesday, August 05, 2014
Bookmark and Share
Enhanced senior management team reflects Company’s commitment to expanding research and development pipeline.

Global Blood Therapeutics has announced the appointment of Hing Sham, Ph.D., to senior vice president of chemistry. The company also announced that Uma Sinha, Ph.D., has been promoted to chief scientific officer.

Brian Metcalf, Ph.D., chief scientific officer since the company was founded and a globally-recognized expert in drug discovery and medicinal chemistry, transitions to a senior advisor role and will continue to contribute to the company’s research and development.

“The appointment of Dr. Sham and promotion of Dr. Sinha add even more depth to a powerful senior management team, building upon the solid scientific foundation we have established in chronic blood diseases,” said Ted W. Love, M.D., chief executive officer, Global Blood Therapeutics. “Drs. Sham, Sinha and Metcalf are true leaders in drug discovery and development, and we are privileged to benefit from their insight and expertise.”

Dr. Sham brings more than 30 years of experience to Global Blood Therapeutics, achieving major accomplishments in pharmaceutical research and discovery throughout his career. During a 24-year tenure at Abbott Laboratories, culminating in his appointment as a distinguished research fellow in global pharmaceutical discovery, Dr. Sham and his team discovered and advanced 10 clinical candidates spanning cardiovascular disease, HIV, oncology and diabetes.

Among his numerous discoveries, Dr. Sham is the co-inventor of Norvir® and the primary inventor of Kaletra®, Abbott Laboratories’ first and second-generation HIV protease inhibitors approved for the treatment of HIV. Dr. Sham was named a Hero of Chemistry in 2003 by the American Chemical Society for improving children’s health and wellness.

After his tenure at Abbott, Dr. Sham served as senior vice president of research and head of chemical sciences at Elan Pharmaceuticals. While at Elan, Dr. Sham led the chemistry team in the discovery of two clinical candidates for the treatment of Alzheimer’s disease. Most recently, Dr. Sham was head of research and development at iOneWorldHealth/, a non-profit pharmaceutical development organization.

Dr. Sham received his Ph.D. in synthetic organic chemistry from the University of Hawaii and completed his post-doctoral training in the department of chemistry at Indiana University. Dr. Sham has published more than 180 scientific articles in peer-reviewed journals and is a named inventor on 81 issued U.S. patents.

Dr. Sinha joined Global Blood Therapeutics in January 2013 as senior vice president, research, bringing 25 years of experience in biotechnology research. She most recently served as vice president, head of biology at Portola Pharmaceuticals. Prior to Portola, she held senior research positions at Millennium Pharmaceuticals and COR Therapeutics. During her tenure at COR, Dr. Sinha and her team were responsible for the initiation and progression of the factor Xa inhibitor programs that have led to the development of betrixaban, currently being studied in a Phase III trial of patients at risk of thrombosis.

At Portola, her team succeeded in the discovery and preclinical development of Andexanet alfa, Cerdulatinib and Syk inhibitors. Andexanet alfa is being studied in two pivotal Phase III studies of reversal of factor Xa inhibitor induced anticoagulation. Cerdulatinib is in a Phase I/II proof of concept study in chronic lymphocytic leukemia and non-Hodgkin lymphoma patients. Dr. Sinha is a named inventor on 31 issued U.S. patents and has published extensively in peer-reviewed scientific journals.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
New Hope for Personalized Treatment of Eczema
Pharmaceutical researchers at Oregon State University have developed a new approach to treat eczema and other inflammatory skin disorders that would use individual tests and advanced science to create personalized treatments based on each person's lipid deficiencies.
Inroads Against Leukaemia
Potential for halting disease in molecule isolated from sea sponges.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Combination Drug Therapy Shrinks Pancreatic Tumors In Mice
Two drugs that affect the structure and function of DNA have been found to block the growth of pancreatic tumor cells in mice, researchers hope the drugs can soon be tested in humans with the disease.
Seeking A Better Way To Design Drugs
NIH funds research at Worcester Polytechnic Institute to advance a new chemical process for more effective drug development and manufacturing.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos